{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain-of-function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a gain-of-function due to increased kinase activity leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "LRRK2 phosphorylates MKKs in vitro, suggesting it acts as a MAPKKK that phosphorylates MLK substrates.",
          "judgment": "Yes",
          "reasoning": "The kinase assay used effectively models the disease mechanism by demonstrating increased kinase activity, which is relevant to the pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control and showed no MKK3/6 phosphorylation, demonstrating that the observed phosphorylation is LRRK2-specific.",
          "judgment": "Yes",
          "reasoning": "Basic controls were included, and the assay was performed with replicates as indicated by the use of multiple LRRK2 variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Comparison of MalE-tagged MKK6 phosphorylation by different LRRK2 variants: wild-type LRRK2, GTPase (Roc) domain mutant LRRK2 R1441C, and the kinase domain mutants LRRK2 G2019S and LRRK2 I2020T.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (G2019S) and other variants (R1441C, I2020T) were used as controls, allowing for a comparison of kinase activity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The signals were normalized to LRRK2 levels determined by Ponceau staining and western blotting. Data analysis was performed using Image Quant software.",
          "judgment": "No",
          "reasoning": "The paper does not provide a direct calculation of OddsPath or robust statistical analyses sufficient to estimate it.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used multiple variants, including LRRK2 G2019S, R1441C, and I2020T, as well as kinase dead controls.",
          "judgment": "At least 11",
          "reasoning": "The study includes a sufficient number of control variants, allowing for a moderate strength conclusion.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 G2019S variant shows increased kinase activity in vitro, consistent with a gain-of-function mechanism leading to neurotoxicity. The study includes appropriate controls and multiple variants, supporting a moderate strength pathogenic classification."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain-of-function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a gain-of-function due to increased kinase activity leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "LRRK2 phosphorylates MKKs in vitro, suggesting it acts as a MAPKKK that phosphorylates MLK substrates.",
          "judgment": "Yes",
          "reasoning": "The kinase assay used effectively models the disease mechanism by demonstrating increased kinase activity, which is relevant to the pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control and showed no MKK3/6 phosphorylation, demonstrating that the observed phosphorylation is LRRK2-specific.",
          "judgment": "Yes",
          "reasoning": "Basic controls were included, and the assay was performed with replicates as indicated by the use of multiple LRRK2 variants.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Comparison of MalE-tagged MKK6 phosphorylation by different LRRK2 variants: wild-type LRRK2, GTPase (Roc) domain mutant LRRK2 R1441C, and the kinase domain mutants LRRK2 G2019S and LRRK2 I2020T.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (G2019S) and other variants (R1441C, I2020T) were used as controls, allowing for a comparison of kinase activity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The signals were normalized to LRRK2 levels determined by Ponceau staining and western blotting. Data analysis was performed using Image Quant software.",
          "judgment": "No",
          "reasoning": "The paper does not provide a direct calculation of OddsPath or robust statistical analyses sufficient to estimate it.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used multiple variants, including LRRK2 G2019S, R1441C, and I2020T, as well as kinase dead controls.",
          "judgment": "At least 11",
          "reasoning": "The study includes a sufficient number of control variants, allowing for a moderate strength conclusion.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 I2020T variant shows increased kinase activity in vitro, consistent with a gain-of-function mechanism leading to neurotoxicity. The study includes appropriate controls and multiple variants, supporting a moderate strength pathogenic classification."
    }
  ]
}
